Investigational drug · Phase 2
EI-001
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Non-segmental Vitiligo.
Phase 2Last checked: Nov 19, 2026Latest source record: Nov 2, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "EI-001"
First trial start
2025
Dec 30, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EI-001", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-segmental Vitiligo
Approved drugs for the same conditions: Immunology and inflammation
Largest trials
Live from ClinicalTrials.gov: studies naming "EI-001" as an intervention, largest first.
Elixiron Immunotherapeutics (Hong Kong) Ltd.Industry
NCT07223229 · 45 participants (planned) · Start Dec 30, 2025 · Primary completion Dec 31, 2026
Drug: EI-001 · For: Non-segmental Vitiligo
Sites: Huntington Beach, California; Hollywood, Florida; Worcester, Massachusetts · 8 sites in all
Elixiron Immunotherapeutics (Hong Kong) Ltd.Industry
NCT04994912 · 35 participants · Start Oct 1, 2021 · Primary completion Jan 7, 2025
Drug: EI-001 · For: Healthy
Sites: Melbourne, Australia; Shanghai, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-segmental Vitiligo
- VC005Phase 35 trials
Jiangsu vcare pharmaceutical technology co., LTD · Non-segmental Vitiligo, Non-Segmental Vitiligo, Atopic Dermatitis
- SHR0302Phase 32 trials
Jiangsu HengRui Medicine Co., Ltd. · Non-segmental Vitiligo, Psoriatic Arthritis
- GIA632Phase 23 trials
Novartis · Atopic Dermatitis, Non-segmental Vitiligo, Cutaneous Lichen Planus
- SHR0302BasePhase 22 trials
Jiangsu HengRui Medicine Co., Ltd. · Vitiligo, Non-segmental Vitiligo
- ACT-777991Phase 21 trial
Idorsia Pharmaceuticals Ltd. · Non-Segmental Vitiligo
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.